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Abstract
The rapid scale-up of highly active antiretroviral therapy (HAART) and use of single dose Nevirapine (SD NVP) for prevention
of mother-to-child transmission (pMTCT) have raised fears about the emergence of resistance to the first line antiretroviral
drug regimens. A cross-sectional study was conducted to determine the prevalence of primary drug resistance (PDR) in a
cohort of young (,25 yrs) HAART-naı ¨ve HIV pregnant women attending antenatal clinics in Chitungwiza, Zimbabwe. Whole
blood was collected in EDTA for CD4 counts, viral load, serological estimation of duration of infection using the BED Calypte
assay and genotyping for drug resistance. Four hundred and seventy-one women, mean age 21 years; SD: 2.1 were enrolled
into the study between 2006 and 2007. Their median CD4 count was 371cells/mL; IQR: 255–511 cells/mL. Two hundred and
thirty-six samples were genotyped for drug resistance. Based on the BED assay, 27% were recently infected (RI) whilst 73%
had long-term infection (LTI). Median CD4 count was higher (p,0.05) in RI than in women with LTI. Only 2 women had drug
resistance mutations; protease I85V and reverse transcriptase Y181C. Prevalence of PDR in Chitungwiza, 4 years after
commencement of the national ART program remained below WHO threshold limit (5%). Frequency of recent infection BED
testing is consistent with high HIV acquisition during pregnancy. With the scale-up of long-term ART programs,
maintenance of proper prescribing practices, continuous monitoring of patients and reinforcement of adherence may
prevent the acquisition and transmission of PDR.
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Introduction
International guidelines recommend genotypic drug resistance
testing among patients initiating antiretroviral therapy (ART)
[1,2,3,4]. However, this is neither affordable nor practical in many
resource limited settings implementing a public health approach to
ART, with standardized low cost first line ARV regimens and
minimal laboratory monitoring. The efficacy of first line regimens
and long term sustainability of ART may be limited by the
emergence of drug resistance [5]. Recent models of infection in
Africa suggest that a decrease in population virus burden due to
increased access to ART coupled with a diminished transmissibil-
ity of drug resistant viruses could decrease HIV incidence [6].
However, public health and patient benefit may be limited by an
increase in risky behaviors and transmission of drug resistant
viruses [7].
PDR has been documented in European and US studies of
recent and acute infection. In these studies, prevalence of PDR
ranges from 6% to 23%. [8,9,10,11,12,13,14]. A large study of
ART naı ¨ve HIV-infected individuals from 40 United States cities
reported a prevalence of drug resistance associated mutations of
12% among chronically infected, newly diagnosed individuals
[15]. In Africa, potential contributors to the emergence and
transmission of drug resistant HIV are intermittent drug supplies,
inadequate patient monitoring, incorrect prescribing practices,
variable adherence and the use of SD NVP in pMTCT programs
[16,17]. Several surveillance studies in Africa estimate the pre-
valence of transmitted drug resistance to be less than 5% [18,19,
20,21,22,23]. However, a few studies in East and Southern Africa
have recently reported evidence of increasing levels of transmitted
drug resistance [24,25].
Systematic drug resistance surveillance to monitor PDR is
recommended in countries scaling-up ART [26]. As part of
monitoring the HIV epidemics, it is also critical to assess PDR in
the newly HIV-infected individuals. Longitudinal cohort studies
for estimation of new infections are prohibitively expensive. A
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HIV-1 BED Incidence Enzyme Immunosorbent Assay (cBED)
assay [27] is the most widely used. The assay identifies infection
within the last 6 months based on the increasing proportion of
anti-HIV IgG in total IgG following sero-conversion [28] and is
recommended by CDC for population-based incidence studies
[27]. For more accurate estimates of incidence, cBED assay in
different subtypes and contexts, results may be adjusted using
population specific false positive rates (FPR) to provide estimates
consistent with longitudinal studies [29,30,31]. There were con-
cerns that the cBED assay in pregnant women may overestimate
recent infection because of haemodilution and immune suppres-
sion of pregnancy, which could delay the maturation of antibodies.
However recent evidence suggest that pregnancy does not affect
the cBED results [32].
We conducted systematic drug resistance surveillance among
young HIV-1 sero-positive pregnant women over a period of two
years (2006–2007) and performed cBED assays to estimate the
frequency of recent infections. The aim of the study was to cha-
racterize contemporary, recently acquired HIV-1 Subtype C drug
resistance mutations among young pregnant women in Zimbabwe.
Materials and Methods
Four hundred and seventy-one HIV-1 antibody positive young
pregnant women attending antenatal clinics in Chitungwiza were
enrolled over a period of two years (2006–2007). Chitungwiza, the
third largest urban center in the country, is located about 25
kilometers south of Harare, the Capital of Zimbabwe. A compre-
hensive demographic questionnaire was administered to determine
if the participants or their sexual partner(s) had exposure to ART.
This was done in order to distinguish acquired/transmitted drug
resistance from drug resistance attributable to ARV use. The study
protocol and the questionnaire used were reviewed and approved
by the Medical Research Council of Zimbabwe, the Research
Council of Zimbabwe and the Stanford University Institutional
Review Board. Signed informed consent was obtained from all
participants.
Whole blood was collected in EDTA for enumeration of CD4
+
T lymphocytes, virus load, detection of drug resistance mutations
and estimation of the duration of infection. CD4
+ T lymphocytes
were enumerated using a Partec Cyflow counter (Cyflow, Partec,
Munster, Germany) within 6 hours of blood collection as pre-
viously described [33,34]. The remaining whole blood was centri-
fuged and plasma was aliquoted and stored at 280uC.
HIV-1 RNA levels were quantified using the standard Roche
Amplicor Version 1.5 assay (Roche Molecular Sciences, Pleasan-
ton CA, USA) in Zimbabwe. Aliquots of plasma were shipped to
Stanford University using dry nitrogen shippers. Upon receipt they
were stored at 280uC until sequenced. For sequencing, the samples
were thawed and ultra centrifuged at 23000 g for 45 minutes at
24uC to pellet virus particles. RNA was extracted from the viral
pellets using a commercial RNA extraction kit (Roche Mole-
cular Diagnostics, NJ), reverse transcribed to cDNA using random
hexamers and the reverse transcriptase enzyme Superscript III
(Invitrogen Corporation, Carlsbad CA). A 1315 bp fragment of the
pol gene covering 99 protease codons and the first 240 codons of the
reverse transcriptase (RT) was amplified using Platinum Taq
(Invitrogen Corporation, Carlsbad CA) polymerase by nested PCR
and sequenced as previously described [35].
Sequences were assembled using Sequencher Version 4.8 (Gene
Codes Corporation, Ann Arbor, MI) and analyzed using the Stan-
ford HIVDB’s QA/QC program which compares new sequences
to other sequences produced from the same laboratory to identify
possible contamination. To aid in quality assurance, neighbor
joining phylogenetic trees were also created using Bioedit version
7.0.0 (Ibis Biosciences, Carlsbad CA) for sequence alignments and
MEGA version 4.0.2 (The Biodesign Institute, Tempe AZ) for
neighbor-joining tree generation. Maximum Likelyhood (ML)
trees were generated in PhyML v 2.4.4 [36], and 1000 replicates
were bootstrapped. The sequences were then analyzed by the
REGA HIV-1 Subtyping tool [37] on the Stanford HIV Data Base
(HIVDB) for subtype identity and to evaluate for inter-subtype
recombination. The Stanford HIVDB HIVSEQ algorithm was
used to check for known drug resistance mutations. HIVDB’s
Calibrated Sequences Program was used to evaluate the sequences
for transmitted drug resistance. The aligned sequences in Bioedit
software were used to generate the Zimbabwean HIV-1 Subtype
C pol consensus sequence.
The cBED assay was conducted according to the manufacture’s
instructions (Calypte Biomedical Corporation, OR). In brief, HIV-
specific IgG were detected in 1:101 diluted plasma samples by the
BED-biotin peptide, followed by a colour reaction with strepta-
vidin-peroxidase. The optical density values were normalized in
every run using a calibrator (normalized OD (ODn) = mean
specimen OD/mean calibrator OD). Specimens with ODn less
than or equal to 1.2 during an initial cBED screening test were
confirmed by further cBED testing of the sample in triplicate. The
median value of the three confirmatory test results was used as the
final ODn value. HIV-1-positive specimens for which the cBED
assay gave a final ODn of less than or equal to 0.8 were classified
as recent HIV-1 infection.
The statistical program STATA version 10 (StataCorp LP,
Texas, USA) was used to perform Chi squared tests for categorical
data and the Student T test for continuous data.
Results
Four hundred and seventy-one pregnant women with a mean
age of 21.5 years (SD: 2.1) participated in this study. Of these,
53.8% (95% CI: 49.3; 58.5) were primigravida. The proportion of
women who reported more than one sexual partner in the past 12
months was 17. 4% (95% CI: 13.9–20.9) and 22.9% (19.0–26.8)
had been previously treated for a sexually transmitted infection
(STI). The mean age of their partners was 28.7 years (SD: 5.8).
The median CD4 count of the 471 women was 371 cells/mL
(IQR: 255–511).
Based on the results of the cBED assay from the 470 women,
27% (125 of 470) were classified as likely to have been infected
within 155 days of sampling or recently infected (RI) and 330
(73%) as long-term infection (LTI). Table 1 summarizes the com-
parison of clinical, demographic and laboratory characteristics of
the RI and LTI.
There was a statistically significant difference between the
median CD4 counts of the RI (440 cells/mL, IQR; 316–555 cells/
mL) and those with LTI (374 cells/mL, IQR; 350–483 cells/mL)
groups (p=0.05).
Plasma HIV RNA viral load quantitations were performed on
samples from the first 105 women enrolled into the study. Twenty-
five of the 105 women were classified as RI and 80 had LTI. The
mean viral load for the women with LTI (3.57 log10 RNA copies/
ml, 95% CI: 3.57–3.94 log10 RNA copies/ml) was not significantly
different (p=0.251) from that of those with RI (3.58 log10 RNA
copies/ml, 95% CI: 3.21–3.94 log10 RNA copies/ml).
The estimated time of conception was calculated for 96 of the
125 RI women (77%). Considering the estimated dates of
conception and the probable timing of infection calculated using
the cBED assay window period of 155 days, 93.9% (93) of the 96
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infected during the current pregnancy.
Genotypic drug resistance testing by population sequencing was
conducted on the first 303 samples collected. Of these, 236 (78%)
were successfully sequenced. Sixty seven (22%) were not amplifi-
able. The first 240 codons of the reverse transcriptase (RT) gene
were sequenced from the 236 women (Genbank accession num-
bers: GQ463284-GQ463339 and HQ874283-HQ874432). One
hundred and seventy five (74%) of these samples also yielded
sequences from Protease (PR). On phylogetic analysis, all the
sequences clustered with HIV-1 subtype C reference sequences;
and were also classified as HIV-1 subtype C by the REGA sub-
typing tool on the Stanford HIVDB and confirmed by calibrated
resistance programme (CPR). All the sequences were subtype C
HIV-1. The PR and RT majority consensus sequence generated
from the 175 and 236 sequences, respectively were 100% identical
to the HIV-1 subtype C consensus sequences from the Los Alamos
HIV database. Using HIVDB’s calibrated resistance program and
the Stanford Drug Resistance Mutation list (2008), two out of 236
(0.85%) sequenced samples had drug resistance mutations. The
mutations present were PR I85V in Subtype C Drug Resistance
(SCR) patient identity number 423 (SCR423), and RT Y181C in
SCR541 selected by PIs and NNRTIs respectively. SCR423 was
misclassified as RI, had exposure to SD NVP in 2004 for pMTCT
of HIV whilst SCR541 had LTI.
The specimen with the Y181C mutation also had the nucleoside
reverse transcriptase inhibitor (NRTI) selected mutation, T69A.
Nineteen other samples (8%) had mutations (Figure 1) that may be
selected by ARV drugs but have also been described in samples
from treatment naı ¨ve patients with varying frequencies. In accor-
dance with the WHO list of transmitted drug resistance mutations
for population surveillance purposes, these secondary drug resis-
tance mutations do not cause or contribute to drug resistance and
therefore are not included as PDR mutations [26]. However, these
mutations can potentially reduce drug susceptibility in association
with other mutations. The frequencies of these mutations in our
subtype C sequences were not statistically different from those of
treatment naı ¨ve patients from the Stanford HIVDB. Some se-
quences contained recently described mutations that may reduce
the susceptibility to etravirine; E28K (0.84%), V90I (0.42%) and
E138Q (0.42%).
The PR and RT majority consensus sequence (50% majority
rule) generated from the 175 and 236 sequences respectively were
identical to the HIV-1 subtype C consensus sequences as defined
by the Los Alamos HIVDB. The Maximum Likelihood (ML) tree
generated from 227 sequences with the first 240 RT codons did
not demonstrate specific clustering of the study sequences.
Discussion
Genotypic drug resistance testing of samples from the 236
women demonstrated little evidence of transmitted or acquired
drug resistance among these young, HIV positive pregnant women
in Chitungwiza in 2006–2007. Surveillance for transmitted drug
resistance is ideally conducted among recently infected individuals
from longitudinal studies with estimated dates of infection. Here
we sought to establish the prevalence of recent infection and
identify PDR among young treatment naı ¨ve women attending
antenatal clinics by including the BED assay to identify women
who may have been recently infected. Young pregnant primi-
gravida women are assumed to have acquired infection within the
last few years and data on ART exposure was also collected as
recommended by the WHO resistance network [20,21,26,38].
The accuracy of cBED assays to estimate recent infection and
incidence in diverse subtypes, populations and settings is con-
troversial. In settings where HIV-1 subtype B predominates, the
assay misclassifies only 2–3% of cases [29]. In Uganda, where
subtypes A and D predominate, the cBED assay estimated an
incidence rate of 6.1% and 6.0% in Masaka and Kakira districts
respectively. However, prospective incidence rates in these same
areas the previous year were 1.7% (Masaka) and 1.4% (Kakira)
suggesting an overestimation of recent infection and misclassifica-
tion by the assay [39]. In high HIV prevalence rural South Africa,
where subtype C predominates, the cBED assay was shown to
more accurately classify patients if locally measured long-term false
positive ratio (FPR) are used but may underestimate incidence
when used with FPR from other settings. FPR is a correction
method to account for non-recently infected who are misclassified
Table 1. Patient demographic data grouped according to their infection duration based on the BED results.
Demographic information All women Long Term Infection Recently Infected p-value
Age, women, mean (SD), years 21.5 (2.1) 21.6 (2.0) 21.2 (2.2) 0.059
Age of husband, mean (SD), years 28.7 (5.8) 28.5 (4.7) 29.5 (5.0) 0.048
Age at 1st menses, mean (SD), years 14.4 (1.6) 14.5 (1.6) 14.2 (1.4) 0.035
Proportion ever been forced to have sex (95% CI) 5.9%
(3.8;8.1)
5.1%
(2.7–7.4)
8.3%
(3.4–13.3)
0.200
Proportion with more than one sexual partner in the past
12 months (95% CI)
17.4
(13.9–20.9)
18.3%
(14.2–22.5)
15%
(8.6–21.3)
0.411
Proportion never been pregnant before (95% CI) 53.8%
(49.3–58.5)
58.4%
(53.1–63.7)
40.8%
(32.1–49.6)
0.001
Proportion with $1 miscarriage in the past (95% CI) 12.4%
(9.2–15.5)
14.2%
(10.4–18.1)
7.1%
(2.4–11.9)
0.050
Proportion with $1 still birth in the past (95% CI) 1.1%
(0.1–2.2)
1.3%
(0.03–2.5)
0.9%
(20.8–2.6)
0.757
Proportion with $1 children dead (95% CI) 10.2%
(7.3–13.1)
11.0%
(7.6–14.4)
8.0%
(3.0–13.1)
0.472
Proportion treated for STIs (95% CI) 22.9%
(19.0–26.8)
25.5%
(20.8–30.2)
15.0%
(8.6–21.4)
0.018
doi:10.1371/journal.pone.0021241.t001
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infection, there is finite time progression to cBED threshold except
in non progressors. The fraction of HIV infected individuals who
have been infected beyond the cBED threshold is the long- term
FPR [30].
A prospective study conducted in Zimbabwe using specimens
from pregnant women with known dates of seroconversion, re-
commended a cut off of 187 days [31] instead of the 155 days
recommended by the cBED kit manufacturer. Studies from South
Africa, Uganda and Zambia have used the 155 day cut off value
[29,30,39,40,41,42,43]. In the current study, there was a modest
decrease in the estimate of recent infection, using the 187 day
ZVITAMBO study cut off, (data not shown). Thus to distinguish
probable RI from LTI on a population basis, it would appear that
either of the two cut-offs may be used.
There was no evidence of PDR in young pregnant ART naı ¨ve
women with recent infection. The low prevalence of PDR in the
studied population is consistent with other studies that have been
conducted in settings that are currently scaling up ART in
southern Africa [20,21,22]. These studies have reported preva-
lence levels of ,5%, the WHO detection threshold limit in
antiretroviral naı ¨ve populations. However, a higher frequency of
PDR has recently been reported from a large study in Rwanda,
South Africa, Uganda and Zambia where slightly more than 5%
drug resistance was identified in samples collected from 2006
through 2009 [24]. Following scaling-up of ART, in resource poor
countries, the WHO developed a protocol called HIV drug
resistance threshold survey for use in the evaluation of the extent of
transmitted HIVDR in ART-naive RI women which was to be
used as a supplement to HIV sentinel serosurveys. In the WHO
protocol, transmitted HIVDR is categorized into three groups;
,5% (low HIVDR), 5–15% (Medium HIVDR) and .15% (High
HIVDR). The ,5% level is the desired threshold for any country
scaling-up ART. Threshold assessment surveys are conducted to
assess if drug resistant HIV is sufficiently prevalent in the country
to indicate a need for sentinel surveillance. In our study, there was
no evidence of PDR in the RI group. SCR423, the woman
misclassified as RI by the cBED assay had exposure to SD NVP in
a previous pregnancy, although the mutation she harbours is not
associated with SD NVP.
There were several limitations encountered in this study. The
prevalence of drug resistance mutations in the study population
was very low, and thus there was no ability to estimate the
frequency of transmitted drug resistance. However, the focus on
young, largely primigravida pregnant women was expected to
identify recent infections. The younger age and significantly higher
CD4 cell numbers among those estimated to have recent infection
provide some evidence for the veracity of the BED assays. Only a
few of the women reported that they or their partners had been
exposed to ART. Of the few women who were exposed to ART
for pMTCT of HIV, one of them misclassified by the cBED assay
as RI, had a drug resistant mutation. We were not able to obtain
direct access to partners of these young women, men who were on
average 8 years older than their wives or partners who may have
been the source of transmitted infection. As estimated by the BED
assay and estimated dates of conception, young pregnant women
are at very high risk of acquiring infection around conception and
early pregnancy. The high percentage of women infected during
pregnancy shows the urgent need for more prevention education
in young women, their spouses and partners.
There was a low sequencing rate for the sample in this study
(78%), which may have been due to storage and shipping conditions.
Figure 1. Secondary drug resistance mutation found in the study population Subtype C Drug Resistance (SCR) compared with data
from treated and treatment naı ¨ve patients in the HIVDB.
doi:10.1371/journal.pone.0021241.g001
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could not be amplified for genotyping did not significantly differ
from those with amplifiable specimens. Unfortunately not all sam-
ples had their viral load measured; this could have helped in
ascertaining the cause of the low amplification rate.
The prevalence of PDR in Chitungwiza, four years after the
commencement of the national ART program, is still far below the
WHO threshold limit of 5%. To preserve the low prevalence of
PDR, proper prescribing practices of ARV drugs, adherence to
ART education should be maintained. Patients should be moni-
tored to identify those failing therapy and provided alternative
therapies, condom promotion and adherence counseling to pre-
vent the spread of drug resistant viruses. As the ART coverage in
Zimbabwe increases during the coming years, monitoring patients
failing ART will be important to track the evolution of drug resis-
tance in addition to continued surveillance for primary, transmitted
drug resistance among drug naı ¨ve individuals.
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